4.3 Review

Developments in smoking cessation interventions for patients with chronic obstructive pulmonary disease in the past 5 years: a scoping review

期刊

EXPERT REVIEW OF RESPIRATORY MEDICINE
卷 16, 期 7, 页码 749-764

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/17476348.2022.2108797

关键词

smoking cessation; review; COPD; quitting rate; access; usage; adverse event; cost

资金

  1. Project of Beijing Institute of Respiratory Diseases
  2. Beijing Municipal Financial Budget [Ysbz2022002]

向作者/读者索取更多资源

This article conducted a scoping review of smoking cessation interventions for COPD patients, and found that the current methods have limited effectiveness in COPD patients. Most of the studies explored new treatment strategies, such as extended treatment and the use of mobile health. They suggested that pharmacotherapy combined with mHealth showed promise for helping COPD smokers quit. However, the overall quality of the existing studies is poor, and more high-quality research is needed.
Introduction Smoking cessation is the most effective strategy for slowing the progression of chronic obstructive pulmonary disease (COPD). However, COPD patients find it difficult to quit smoking with standard cessation interventions. Areas covered A scoping review of smoking cessation for COPD patients was conducted by searching the MEDLINE, Embase, and Cochrane Library databases for all studies published between 1 January 2016 and 22 September 2021. Four themes were set up and 47 studies were included eventually. The majority of the included studies (61.7%, 29/47) investigated efficacy and effectiveness, including new strategies for extended treatment and mobile health (mHealth) delivery approach. Studies examining accessibility and utilization (31.9%, 15/47), safety (10.6%, 5/47), and health economics (6.4%, 3/47) were also reviewed. The quality of the included randomized controlled trials was also evaluated. Expert opinion Pharmacotherapy combined with behavioral interventions delivered via mHealth may be a promising strategy to help COPD smokers quit. However, the overall quality of the current studies is poor, making it challenging for clinicians to make informed decisions. Future high-quality studies are needed to provide conclusive evidence on the optimal pharmacotherapies and the most cost-effective comprehensive smoking cessation interventions, particularly those integrated into disease management for smokers with COPD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据